Premium
Psychopharmacological profile of clenbuterol
Author(s) -
Francès H.,
Poncelet M.,
Danti S.,
Goldschmidt P.,
Simon P.
Publication year - 1983
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430030407
Subject(s) - clenbuterol , salbutamol , oxotremorine , apomorphine , pharmacology , yohimbine , agonist , endocrinology , reserpine , medicine , pentobarbital , chemistry , antagonist , receptor , asthma
Clenbuterol, a β‐adrenergic agonist known to enter the brain, has been studied in mice with a set of psychopharmacological tests. Clenbuterol has an ambiguous sedative effect: it reduces motor activity in a dose‐dependent manner without modifying exploratory behavior in the open field; it does not potentiate the effect of pentobarbital. Clenbuterol decreases the search for food in starved mice. Regarding the tests in animals which are expected to reflect antidepressant activity in man (hypothermias induced by reserpine, oxotremorine or a high dose of apomorphine, potentiation of yohimbine toxicity) clenbuterol acts at doses much lower than those required with two other β‐adrenergic agonists, isoproterenol and salbutamol. Moreover, the active doses of clenbuterol and salbutamol being nearly the same at a peripheral level, the ratio of the centrally and peripherally active doses is highly in favor of clenbuterol. This suggests that the effects of clenbuterol on depressed patients should be studied.